Lu Huimin, Yang Dujiang, Zhang Ling, Lu Shan, Ye Jun, Li Mao, Hu Weiming
Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Oncol Lett. 2019 May;17(5):4633-4639. doi: 10.3892/ol.2019.10111. Epub 2019 Mar 5.
Long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) is a newly identified long non-coding RNA, which has demonstrated antitumor activities in various types of cancer. The present study aimed to investigate the role of Linc-pint in pancreatic ductal adenocarcinoma (PDAC). Plasma samples from patients with PDAC, and PDAC and normal cell lines were used in the study. Gene expression was analyzed by reverse transcription-quantitative polymerase chain reaction. Western blotting was used to assess protein level. Transforming growth factor β1 (TGF-β1) plasma level was determined by ELISA. Cancer cell proliferation was measured with the Cell Counting Kit-8 assy. The results demonstrated that Linc-pint plasma levels were significantly lower in patients with stage 0-1 PDAC compared with healthy controls. In addition, Linc-pint downregulation effectively distinguished patients with PDAC from healthy controls. Linc-pint and TGF-β1 plasma levels were positively correlated in patients with PDAC but not in healthy controls. Furthermore, Linc-pint overexpression upregulated TGF-β1 expression in PDAC cells but not in normal pancreatic ductal cells; however, exogenous TGF-β1 exhibited no significant effects on Linc-pint expression. Linc-pint overexpression and TGF-β1 both inhibited PDAC cell proliferation, whereas treatment with a TGF-β inhibitor reduced their inhibitory effects on cell proliferation. In conclusion, results from the present study suggested that Linc-pint may inhibit early stage PDAC growth through TGF-β pathway activation.
长链基因间非编码RNA，p53诱导转录本（Linc-pint）是一种新发现的长链非编码RNA，已在多种癌症中显示出抗肿瘤活性。本研究旨在探讨Linc-pint在胰腺导管腺癌（PDAC）中的作用。研究使用了PDAC患者的血浆样本以及PDAC和正常细胞系。通过逆转录定量聚合酶链反应分析基因表达。采用蛋白质印迹法评估蛋白质水平。通过酶联免疫吸附测定法测定转化生长因子β1（TGF-β1）的血浆水平。使用细胞计数试剂盒-8检测法测量癌细胞增殖。结果表明，与健康对照相比，0-1期PDAC患者的Linc-pint血浆水平显著降低。此外，Linc-pint下调能有效区分PDAC患者与健康对照。在PDAC患者中，Linc-pint和TGF-β1血浆水平呈正相关，但在健康对照中无此相关性。此外，Linc-pint过表达上调了PDAC细胞中TGF-β1的表达，但在正常胰腺导管细胞中未上调；然而，外源性TGF-β1对Linc-pint表达无显著影响。Linc-pint过表达和TGF-β1均抑制PDAC细胞增殖，而用TGF-β抑制剂处理可降低它们对细胞增殖的抑制作用。总之，本研究结果表明，Linc-pint可能通过激活TGF-β途径抑制早期PDAC的生长。
